The immune response in atherosclerosis: a double-edged sword, Nat Rev Immunol, vol.6, pp.508-527, 2006. ,
Dendritic cells in atherosclerotic disease, Clin Immunol, vol.134, pp.25-32, 2010. ,
Oxidized low-density lipoprotein promotes mature dendritic cell transition from differentiating monocyte, J Immunol, vol.167, pp.3785-91, 2001. ,
URL : https://hal.archives-ouvertes.fr/inserm-00136264
Sensing environmental lipids by dendritic cell modulates its function, J Immunol, vol.172, pp.54-60, 2004. ,
URL : https://hal.archives-ouvertes.fr/inserm-00136798
Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune responses, Vaccine, vol.24, pp.1254-63, 2006. ,
URL : https://hal.archives-ouvertes.fr/inserm-00137028
High-density lipoprotein phospholipids interfere with dendritic cell Th1 functional maturation, Immunobiology, vol.217, pp.91-100, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-02443454
Emerging roles of secreted phospholipase A2 enzymes: Lessons from transgenic and knockout mice, Biochimie, vol.92, pp.561-82, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00497527
Biochemistry and physiology of mammalian secreted phospholipases A2, Annu Rev Biochem, vol.77, pp.495-520, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00315356
Secretory phospholipase A2 induces dendritic cell maturation, Eur J Immunol, vol.34, pp.2293-302, 2004. ,
URL : https://hal.archives-ouvertes.fr/inserm-00136390
Dendritic-cell activation by secretory phospholipase A2, Blood, vol.105, pp.3583-3590, 2005. ,
Group V secretory phospholipase A2 reveals its role in house dust mite-induced allergic pulmonary inflammation by regulation of dendritic cell function, J Immunol, vol.185, pp.4430-4438, 2010. ,
Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function, Faseb J, vol.20, pp.2547-2556, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-00170587
Expression of secretory phospholipase A2s in human atherosclerosis development, Atherosclerosis, vol.196, pp.81-91, 2008. ,
Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation, J Biol Chem, vol.277, pp.29116-29140, 2002. ,
Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A(2), Biochim Biophys Acta, vol.1736, pp.38-50, 2005. ,
Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics, Anal Bioanal Chem, vol.400, pp.1829-1871, 2011. ,
Group X secreted phospholipase A2 proenzyme is matured by a furin-like protein convertase and release arachidonic acid inside of human HEK293 cells, J Biol Chem, 2011. ,
Phospholipolyzed LDL induces an inflammatory response in endothelial cells through endoplasmic reticulum stress signaling, FASEB J, vol.24, pp.3284-97, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00497550
Extracellular phospholipases in atherosclerosis, Biochimie, vol.92, pp.594-600, 2010. ,
Exogenously added human group X secreted phospholipase A(2) but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells, J Biol Chem, vol.275, pp.3179-91, 2000. ,
The proinflammatory mediator Platelet Activating Factor is an effective substrate for human group X secreted phospholipase A2, Biochim Biophys Acta, vol.1761, pp.1093-1102, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-00169124
Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry, J Lipid Res, vol.50, pp.574-85, 2009. ,
Hydrolysis of minor glycerophospholipids of plasma lipoproteins by human group IIA, V and X secretory phospholipases A2, Biochim Biophys Acta, vol.1771, pp.5-19, 2007. ,
URL : https://hal.archives-ouvertes.fr/hal-00170653
Lipoprotein modification by secretory phospholipase A(2) enzymes contributes to the initiation and progression of atherosclerosis, Curr Opin Lipidol, vol.20, pp.421-428, 2009. ,
Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study, Arterioscler Thromb Vasc Biol, vol.27, pp.1177-83, 2007. ,
Comparison of effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man, J Lipid Res, vol.26, pp.194-202, 1985. ,
The impact of eicosanoids on the crosstalk between innate and adaptive immunity: the key roles of dendritic cells, Tissue Antigens, vol.65, pp.507-521, 2005. ,
Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo, Immunity, vol.11, pp.753-61, 1999. ,
Progress and challenges in translating the biology of atherosclerosis, Nature, vol.473, pp.317-342, 2011. ,
,
, Enhances TLR4 Signaling in Macrophages, J Immunol, vol.187, pp.482-491, 2011.
, DCs received 50µg/ml LDL, or LDL-X or the equivalent amount of hGX-sPLA 2 brought by LDL-X in the cell culture (X 25, 10 or 5). When mentioned, the sPLA 2 inhibitor LY329722 (LY) was added 15 min before. (B-D) The mean fluorescence intensity for CD86 labeling was normalized to control iDCs receiving LDL buffer, 200 or 100nM hGX-sPLA 2 for 24h at RT (LDL-X), vol.500
, Functional DC maturation induced by LDL-X
, LDL-X was generated by treatment with 500nM hGX-sPLA 2 for 24h at RT. DCs received 50µg/ml LDL or LDL-X or 25nM hGX-sPLA 2 alone (X) or control buffer. DC supernatants were collected at day 6 and assayed for cytokines and chemokines secretion. Results represent the mean concentration±SE from 3 independent experiments. (B) LDL-X
, After a 24h-treatment with 50µg/ml LDL or LDL-X or buffer, DCs were washed and cocultured in triplicates for 5 days with allogeneic T cells. Mean IFN? secretion in MLR supernatants was normalized to control DCs for each experiment (fold increase). Results represent the mean±SE from 5 independent experiments
, LPC and fatty acids produced by sPLA 2 activity can modulate DC maturation
, B) 40µM LPC in the presence or absence of 50µg/ml LDL (C) 40µM LPC16:0 or LPC18:0 or LPC18:1. Their phenotype was analyzed at day 6 and CD86 expression is presented as fold induction compared to control iDCs. Results represent the mean±SE for, DCs were treated at day 5 for 24h with (A) 20 to 50µM LPC, vol.6
, DCs were treated at day 5 for 24h with 40µM fatty acid with or without 40µM LPC18:0 in the 25 presence of 50µg/ml LDL. DC phenotype was analyzed and CD86 expression is presented as fold induction compared to control iDCs